16.10.2023 - Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatmentNEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) - Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a . Seite 1